We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 63

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Federal Circuit finds Yaz patent obvious

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 25 2013

In Bayer Healthcare Pharmaceuticals, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court and held that Bayer's

Supreme Court oral arguments in ACLU Myriad gene patent case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • April 15 2013

On April 15, 2013, the Supreme Court heard oral arguments in one of the most controversial and publicized biotech patent cases-the "ACLUMyriad" gene

Briefing the Supreme Court in Myriad

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 28 2013

March 15, 2013 was a big deadline for patent applicants seeking to secure first-to-invent filing dates for U.S. patent applications, but April 15

Federal Circuit upholds Fentora patents, but affirms non-infringement

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • February 26 2013

In Cephalon, Inc. v. Watson Pharmaceuticals, Inc., the Federal Circuit reversed the district court's finding that two Orange Book-listed patents for

Supreme Court to hear androgel reverse payment case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 10 2013

The Supreme Court granted certiorari in Federal Trade Commission v. Watson Pharmaceuticals, Inc., to address whether and when "reverse payment" agreements

An update on patenting personalized medicine after Prometheus

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 4 2012

While the Supreme Court just granted certiorari in Myriad, case law surrounding the patent-eligibility of diagnostic and therapeutic personalized medicine has continued to develop in the wake of Mayo v. Prometheus

Supreme Court grants certiorari in Myriad to decide whether human genes can be patented

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 30 2012

On November 30, 2012, the Supreme Court granted certiorari in the “ACLUMyriad” gene patenting case (formally styled as Association for Molecular Pathology v. Genetics, Inc., et al.), guaranteeing that the debate over the patent-eligibility of human genes will continue for another round

India IP board invalidates Roche Hepatitis C patent, cites KSR

  • Foley & Lardner LLP
  • -
  • India
  • -
  • November 5 2012

In a decision issued November 2, 2012, the Intellectual Property Appellate Board of India (IPAB) determined in a post-grant opposition proceeding that Roche’s patent covering its Pegasys (pegylated interferon alfa-2a) product for the treatment of Hepatitis C, is invalid as obvious

Federal Circuit finds Treximet patents non-obvious and infringed

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • October 18 2012

In Pozen, Inc. v. Par Pharmaceutical Inc., the Federal Circuit upheld the district court’s determination that the patents at issue were not invalid as obvious and were infringed by the subject Abbreviated New Drug Applications (ANDAs

Current Search

Suggested Facets

Author

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy